Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Relay Therapeutics ( (RLAY) ) has issued an announcement.
Relay Therapeutics announced participation in the 43rd Annual J.P. Morgan Healthcare Conference, highlighting progress in their clinical programs, notably the RLY-2608, aimed at breast cancer. The company anticipates starting pivotal trials and clinical data updates in 2025, supported by a strong financial position and extensive global clinical experience, targeting significant market opportunities in the oncology sector.
More about Relay Therapeutics
Relay Therapeutics is a biotechnology company focusing on developing therapies for cancer and genetic diseases. Utilizing their proprietary Dynamo platform, the company is working on targeted treatments for breast cancer, vascular malformations, and other solid tumors, emphasizing mutant-selective PI3Kα inhibitors.
YTD Price Performance: 3.49%
Average Trading Volume: 2,061,547
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $744.9M
For an in-depth examination of RLAY stock, go to TipRanks’ Stock Analysis page.
